Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
1
25%
Ph not_applicable
1
25%
Ph early_phase_1
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 21 (25.0%)
N/A1 (25.0%)

Trials by Status

completed375%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Inflammatory Challenge in Human Aggression.

NCT06665074
completednot_applicable

Determining the Fingerprint of Endotoxin Tolerance

NCT06801873
completedearly_phase_1

Assessing NOS Uptake With PET Imaging in Lung Inflammation

NCT02151552
completedphase_1

PET Imaging of Endotoxin-induced iNOS Activation

NCT01407796

Clinical Trials (4)

Showing 4 of 4 trials
NCT06665074Phase 2

Inflammatory Challenge in Human Aggression.

Recruiting
NCT06801873Not Applicable

Determining the Fingerprint of Endotoxin Tolerance

Completed
NCT02151552Early Phase 1

Assessing NOS Uptake With PET Imaging in Lung Inflammation

Completed
NCT01407796Phase 1

PET Imaging of Endotoxin-induced iNOS Activation

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4